Quarterly Sales Approved
February 19, 2021 (Est)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Oxbryta (voxelotor) for Sickle Cell Anemia Quarterly Sales (Approved)
WHAT IS THE NEXT CATALYST EVENT?
Quarterly Sales (Approved)
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
February 19, 2020
Q3 2020 sales $36.9M
Updated by MV
Oxbryta (voxelotor), cystic fibrosis, GBT, genetic disorder
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post